Adherence Monitoring System in Managing Myelosuppression in Patients With Newly Diagnosed Malignant Gliomas Receiving Temozolomide and Radiation Therapy
Comparative Development of Data Driven Systems for Insuring Timely Monitoring for Brain Tumor Patients for Management of Myelosuppression
Sponsor: National Cancer Institute (NCI)
Terminated
Support Staff Left Institution
Other terminated trials from National Cancer Institute (NCI)
Other Malignant Glioma trials with similar outcome
This observational or N/A phase trial investigates Malignant Glioma and Myelosuppression and is currently terminated or withdrawn. National Cancer Institute (NCI) leads this study, which shows 10 recorded versions since 2015 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.
Status Flow
Change History
10 versions recorded-
Sep 2024 — Present [monthly]
Terminated
-
Jul 2024 — Sep 2024 [monthly]
Terminated
-
Jan 2021 — Jul 2024 [monthly]
Terminated
-
Aug 2018 — Jan 2021 [monthly]
Terminated
-
Jun 2018 — Aug 2018 [monthly]
Terminated
▶ Show 5 earlier versions
-
Apr 2018 — Jun 2018 [monthly]
Terminated
Phase: NA → None
-
Aug 2017 — Apr 2018 [monthly]
Terminated NA
Status: Suspended → Terminated
-
Jun 2017 — Aug 2017 [monthly]
Suspended NA
-
Apr 2017 — Jun 2017 [monthly]
Suspended NA
-
Jan 2017 — Apr 2017 [monthly]
Suspended NA
First recorded
Feb 2015
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- National Cancer Institute (NCI)
- Wake Forest University Health Sciences
For direct contact, visit the study record on ClinicalTrials.gov .